Table 2.
Distribution of the Studied Patients by the Disease and Health-Related Characteristics (N = 120).
| Variables | No. (%) |
|---|---|
| RMDs | |
| RA | 87 (72.5%) |
| SLE | 23 (19.2%) |
| Others | 10 (8.3%) |
| Duration of RMDs (years) | |
| <5 | 50 (41.7%) |
| 5-10 | 41 (34.2%) |
| More than 10 | 29 (24.2%) |
| Medications for RMDs | |
| NSAIDS | 21 (17.5%) |
| Steroids | 9 (7.5%) |
| Nonbiologic DMARDs: | 117 (97.5%) |
| 1–2 | 28 (23.3%) |
| 3+ | 89 (74.2%) |
| Biologic DMARDs | 5 (4.2%) |
| Other treatment | |
| ACEI | 80 (66.7%) |
| Vitamin D | 40 (33.3%) |
| Frequency of dispensing the RMDs treatment | |
| Monthly | 118 (98.3%) |
| Others | 2 (1.7%) |
| Dispensing person of the RMDs treatment | |
| Patient | 118 (98.3%) |
| Caregiver | 2 (1.7%) |
| Health insurance | |
| Public insurance | 112 (93.3%) |
| Out-of-pocket | 1 (0.8%) |
| Comorbid conditions | |
| None | 80 (66.7%) |
| Single | 12 (10.0%) |
| Multiple | 28 (23.3%) |
| Types of comorbidities | |
| Hypertension | 12 (10.0%) |
| Diabetes mellitus | 13 (10.8%) |
| Others | 38 (31.7%) |
| COVID-19-related history | |
| Confirmed positivity | 4 (3.3%) |
| Contact with confirmed cases | 6 (5.0%) |
| Perceived health and well-being, mean (SD), range | |
| Physical health | 1.80 (0.89), 0 – 4 |
| Mental health | 1.04 (1.16), 0 – 4 |
| Social life | 1.58 (0.84), 0 – 4 |
| Overall quality of life | 4.93 (0.70), 0 – 10 |
| FCV-19S, mean (SD), range | 26.0 (7.6), 7–35 |
| COV19–impact on QoL, mean (SD), range | 22.6 (6.7), 6–30 |
| Kessler's scale for psychological distress (K6), Mean (SD), range | 16.5 (6.2), 0 – 24 |
| Level of psychological distress, n (%) | |
| Low | 10 (8.3%) |
| Moderate | 38 (31.7) |
| High | 72 (60.0%) |
RMD = rheumatic and musculoskeletal disease; RA = rheumatic arthritis; DMARDs = disease-modifying antirheumatic drugs; ACEI = angiotensin-converting enzyme inhibitors; FCV-19S = fear of COVID-19 scale; SLE = systemic lupus erythematosus; QoL = quality of life; NSAID = non-steroidal anti-inflammatory drugs.